These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 17599850)

  • 1. The perfect storm--drug safety and rosiglitazone.
    Hellman R
    Endocr Pract; 2007; 13(3):217-8. PubMed ID: 17599850
    [No Abstract]   [Full Text] [Related]  

  • 2. Rosiglitazone: a thunderstorm from scarce and fragile data.
    Mulrow CD; Cornell J; Localio AR
    Ann Intern Med; 2007 Oct; 147(8):585-7. PubMed ID: 17938398
    [No Abstract]   [Full Text] [Related]  

  • 3. Rosiglitazone--continued uncertainty about safety.
    Drazen JM; Morrissey S; Curfman GD
    N Engl J Med; 2007 Jul; 357(1):63-4. PubMed ID: 17551160
    [No Abstract]   [Full Text] [Related]  

  • 4. Rosiglitazone and cardiovascular risk.
    Kaul S; Diamond GA
    Curr Atheroscler Rep; 2008 Oct; 10(5):398-404. PubMed ID: 18706281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rosiglitazone and cardiovascular risk.
    Mannucci E; Monami M; Marchionni N
    N Engl J Med; 2007 Aug; 357(9):938; author reply 939-40. PubMed ID: 17806136
    [No Abstract]   [Full Text] [Related]  

  • 6. The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience.
    Hiatt WR; Kaul S; Smith RJ
    N Engl J Med; 2013 Oct; 369(14):1285-7. PubMed ID: 23992603
    [No Abstract]   [Full Text] [Related]  

  • 7. Rosiglitazone and cardiovascular risk.
    Bracken MB
    N Engl J Med; 2007 Aug; 357(9):937-8; author reply 939-40. PubMed ID: 17761600
    [No Abstract]   [Full Text] [Related]  

  • 8. Analytical issues regarding rosiglitazone meta-analysis.
    Claggett B; Wei LJ
    Arch Intern Med; 2011 Jan; 171(2):179-80; author reply 180. PubMed ID: 21263111
    [No Abstract]   [Full Text] [Related]  

  • 9. Rosiglitazone and cardiovascular risk.
    Diamond GA; Kaul S
    N Engl J Med; 2007 Aug; 357(9):938-9; author reply 939-40. PubMed ID: 17806135
    [No Abstract]   [Full Text] [Related]  

  • 10. The record on rosiglitazone and the risk of myocardial infarction.
    Psaty BM; Furberg CD
    N Engl J Med; 2007 Jul; 357(1):67-9. PubMed ID: 17551162
    [No Abstract]   [Full Text] [Related]  

  • 11. Thiazolidinediones and clinical diabetes management: new challenges for the fall of 2007.
    Boyle P
    South Med J; 2007 Nov; 100(11):1063-4. PubMed ID: 17984728
    [No Abstract]   [Full Text] [Related]  

  • 12. Outlook on diabetes drug less than rosy. Early work suggests that rosiglitazone (Avandia) may not be best for the heart.
    Harv Heart Lett; 2007 Aug; 17(12):1-2. PubMed ID: 17717888
    [No Abstract]   [Full Text] [Related]  

  • 13. Perspective: effect of rosiglitazone on cardiovascular outcomes.
    Nissen SE
    Curr Cardiol Rep; 2007 Sep; 9(5):343-4. PubMed ID: 17877927
    [No Abstract]   [Full Text] [Related]  

  • 14. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death.
    Diamond GA; Bax L; Kaul S
    Ann Intern Med; 2007 Oct; 147(8):578-81. PubMed ID: 17679700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety of rosiglitazone in the treatment of type 2 diabetes.
    Singh S; Loke YK
    Expert Opin Drug Saf; 2008 Sep; 7(5):579-85. PubMed ID: 18759710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Doubts as to the cardiovascular safety of rosiglitazone].
    Hoekstra JB; Bossuyt PM; de Vries JH
    Ned Tijdschr Geneeskd; 2007 Jun; 151(26):1449-50. PubMed ID: 17633972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Was there really any evidence that rosiglitazone increased the risk of myocardial infarction or death from cardiovascular causes?
    Stone JC; Furuya-Kanamori L; Barendregt JJ; Doi SA
    Pharmacoepidemiol Drug Saf; 2015 Mar; 24(3):223-7. PubMed ID: 25515780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Doubts as to the cardiovascular safety of rosiglitazone].
    Wolffenbuttel BH
    Ned Tijdschr Geneeskd; 2007 Oct; 151(40):2236-7; author reply 2237. PubMed ID: 17969577
    [No Abstract]   [Full Text] [Related]  

  • 19. Cardiovascular safety of rosiglitazone.
    Krall RL
    Lancet; 2007 Jun; 369(9578):1995-1996. PubMed ID: 17574083
    [No Abstract]   [Full Text] [Related]  

  • 20. Rosiglitazone and cardiovascular disease revisited.
    Davis TM; Prins JB
    Med J Aust; 2010 Aug; 193(3):134-5. PubMed ID: 20678037
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.